Holen Sie sich die Stockscreener-App
54.10
1.55%
-0.85
Schlusskurs vom Vortag:
$54.95
Offen:
$55.67
24-Stunden-Volumen:
695.77K
Relative Volume:
0.49
Marktkapitalisierung:
$7.77B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-507.65M
KGV:
-11.76
EPS:
-4.6
Netto-Cashflow:
$-616.24M
1W Leistung:
-3.65%
1M Leistung:
+17.56%
6M Leistung:
+71.47%
1J Leistung:
-35.47%
1-Tages-Spanne:
$54.03
$56.69
1-Wochen-Bereich:
$51.34
$58.00
52-Wochen-Spanne:
$27.66
$85.57
Vaxcyte Inc Stock (PCVX) Company Profile
Firmenname
Vaxcyte Inc
Sektor
Branche
Telefon
650-837-0111
Adresse
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Compare PCVX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
54.10 | 7.89B | 0 | -507.65M | -616.24M | -4.60 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Vaxcyte Inc Stock (PCVX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-07 | Bestätigt | Needham | Buy |
| 2025-09-12 | Eingeleitet | Goldman | Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-20 | Eingeleitet | Goldman | Buy |
| 2023-12-07 | Eingeleitet | Mizuho | Buy |
| 2023-04-18 | Eingeleitet | TD Cowen | Outperform |
| 2023-01-03 | Bestätigt | Needham | Buy |
| 2022-12-15 | Eingeleitet | Guggenheim | Buy |
| 2022-11-17 | Eingeleitet | BTIG Research | Buy |
| 2021-12-29 | Fortgesetzt | Jefferies | Buy |
| 2021-06-24 | Fortgesetzt | Jefferies | Buy |
| 2020-07-07 | Eingeleitet | BofA Securities | Buy |
| 2020-07-07 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-07-07 | Eingeleitet | Needham | Buy |
Alle ansehen
Vaxcyte Inc Aktie (PCVX) Neueste Nachrichten
Is now the right time to enter Vaxcyte Inc.Market Activity Report & Safe Capital Growth Tips - mfd.ru
Vaxcyte (PCVX) Initiates Phase 3 Trial for VAX-31 Vaccine in Adu - GuruFocus
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial Evaluating VAX-31 in Adults Previously Vaccinated with Lower-Valency Pneumococcal Vaccines - The Manila Times
Vaxcyte Doses First Participants in OPUS-3 Phase 3 Trial - GlobeNewswire
Vaxcyte to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on February 24, 2026 - Sahm
Vaxcyte, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 - Quiver Quantitative
Vaxcyte to Report Fourth Quarter and Full Year 2025 - GlobeNewswire
IPO Launch: What is the target price for Vaxcyte Inc stockMarket Risk Report & Safe Swing Trade Setups - baoquankhu1.vn
Vaxcyte, Inc. (NASDAQ:PCVX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Valuation Update: Is Vaxcyte Inc affected by consumer sentimentSwing Trade & Fast Gaining Stock Strategy Reports - baoquankhu1.vn
Vaxcyte, Inc. $PCVX Shares Bought by Federated Hermes Inc. - MarketBeat
Aug Wrap: Does Stepan Company have consistent dividend growth2025 AllTime Highs & Fast Gain Swing Alerts - baoquankhu1.vn
How Investors May Respond To Vaxcyte (PCVX) Raising $550 Million To Fund Pneumococcal Vaccine Pipeline - Sahm
Vaxcyte to Present at the Guggenheim Emerging Outlook: Biotech Summit - 富途牛牛
Commit To Buy Vaxcyte At $45, Earn 19.3% Annualized Using Options - Nasdaq
Technical Reactions to PCVX Trends in Macro Strategies - Stock Traders Daily
Vaxcyte closes $632.5 million public offering of common stock By Investing.com - Investing.com India
Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - The Manila Times
Is It Time To Reassess Vaxcyte (PCVX) After Recent Share Price Recovery - Yahoo Finance
Assessing Vaxcyte (PCVX) Valuation After Recent Share Price Momentum - Yahoo Finance
Vaxcyte Funding And Late-Stage Trials Put Valuation In Focus - Yahoo Finance
Vaxcyte (NASDAQ:PCVX) Stock Price Up 8.1%Time to Buy? - MarketBeat
Vaxcyte, Inc. (PCVX) Stock Analysis: Exploring A Potential 90.61% Upside For Investors - DirectorsTalk Interviews
Vaxcyte Announces Closing of $632.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - Investing News Network
Vaxcyte Closes Public Offering of Shares - marketscreener.com
Vaxcyte Completes Public Equity Offering, Bolstering Capital Position - TipRanks
Vaxcyte closes $632.5 million public offering of common stock - Investing.com
Vaxcyte, Inc. Completes $632.5 Million Public Offering of Common Stock - Quiver Quantitative
Guggenheim Reiterates Buy Rating on Vaxcyte (PCVX) at $116 Targe - GuruFocus
Vaxcyte (NASDAQ:PCVX) Earns Buy Rating from Guggenheim - MarketBeat
Sentiment Recap: Whats the RSI of Vaxcyte Inc stock2025 Retail Activity & AI Driven Stock Reports - baoquankhu1.vn
Top Biotech Stocks To Follow TodayFebruary 1st - MarketBeat
Vaxcyte launches proposed $500M public offering of stock, warrants - MSN
Vaxcyte prices $550 million public offering of common stock By Investing.com - Investing.com Nigeria
Eikon aims high for NASDAQ listing: Public Equity Report - BioCentury
Latham & Watkins Advises on Vaxcyte’s US$550 Million Public Offering - Latham & Watkins LLP
Vaxcyte launches $500 million public offering of common stock By Investing.com - au.investing.com
Biotech Stocks To Follow TodayJanuary 30th - MarketBeat
PCVX Increases Common Stock Offering to $550 Million - GuruFocus
Vaxcyte (NASDAQ:PCVX) Shares Gap UpStill a Buy? - MarketBeat
Vaccine maker looks to raise half a billion dollars to attack an $8 billion market - The Business Journals
Vaxcyte edges higher after upsized $550 mln equity raise - TradingView
Vaxcyte Secures $550 Million to Advance Vaccine Pipeline and Manufacturing - AD HOC NEWS
Vaxcyte Prices $550 Million Common Stock Offering - marketscreener.com
Vaxcyte Announces Pricing of $550 Million Public Offering - Investing News Network
Vaxcyte prices $550 million public offering of common stock - Investing.com
Vaxcyte sells 11M new shares in $550M stock offering at $50 - stocktitan.net
PCVX Offering Managed by Top Financial Firms - GuruFocus
Vaxcyte (PCVX) Launches Share Offering Priced at $50 - GuruFocus
Finanzdaten der Vaxcyte Inc-Aktie (PCVX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.12%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):